GlassScriptPhysician profile
Heather A Ross
NPI 1912319401
$2,629.17
in general payments reported to CMS, 2019-2025
21 companies · $556 in 2025
The $556 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.97 · 2022: $333 · 2023: $751 · 2024: $934 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,240.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $765.76 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $556.78 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $340.50 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $252.30 | 2022-2025 | Repatha, Prolia, Evenity |
| Exact Sciences Corporation | $214.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $161.78 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.84 | 2023-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $37.32 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $31.45 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $25.61 | 2022-2025 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $24.28 | 2025 | |
| Axsome Therapeutics, INC. | $22.98 | 2025 | Symbravo |
| Otsuka America Pharmaceutical, INC. | $21.24 | 2025 | Rexulti |
| Astellas Pharma US INC | $20.85 | 2023 | Veozah |
| Dexcom, INC. | $20.22 | 2025 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.92 | 2025 | Caplyta |
| Neos Therapeutics, LP | $17.60 | 2023 | Adzenys Xr-Odt |
| Medtronic, INC. | $16.43 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.62 | 2022 | |
| Lundbeck LLC | $13.53 | 2022 | |
| Glaxosmithkline, LLC. | $13.02 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.